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Rhabdomyolysis due to lamivudine 
re-administration in a patient with HBV-
related hepatic failure caused by interruption  
of lamivudine and adefovir
To the Editor,
A 47-year-old man with chronic hepatitis B was admitted to 
Kobe Asahi Hospital on January 26, 2014 presenting with hepatic 
failure. Laboratory examinations revealed the following: total 
bilirubin, 3.39mg/dl; aminotransferases, AST, 2,700U/l; ALT, 
1,800U/l; prothrombin time 40.8%; HBeAg(+); HBeAb(-) and 
HBV DNA, 9.1 log IU/ml (Real-time detection PCR test, LSI 
Medience Corporation, Tokyo). Under the diagnosis of chronic 
hepatitis B (stage F3), lamivudine (100mg once daily) had been 
administered since September 2004.
Liver function worsened in September 2005, and YIDD 
mutation was detected. IFN-α 300MU/mg three times a week 
was administered from October 2005 to August 2006.
In September 2006, IFN treatment was replaced by adefovir 
(10mg once daily). Liver function and virological markers 
improved steadily from April 2007 to October 2013. Laboratory 
examinations in June 2013 revealed the following: AST, 28U/l; 
ALT, 9U/l; HBeAg (-); HBeAb (-); HBV DNA was not detectable. 
The therapy with lamivudine and adefovir was suspended by the 
patient in November 2013.  
On January 26, 2014 when he developed hepatic failure, 
administration of lamivudine and adefovir was resumed 
together with entecavir. On February 19, the level of creatine 
phosphokinase (CPK) was high (4,195 IU/l), and the levels of 
blood and urine myoglobin reached 648 ng/ml (normal <100 
ng/ml) and 570 ng/ml (<8.5 ng/ml), respectively. Troponin T 
was negative and the isozyme pattern of CPK was type MM. No 
evidence of muscle trauma, infection, or other metabolic signs 
were present, and the patient demonstrated no specific symptoms. 
The drugs administered at the time of increased serum CPK 
were ursodeoxycholic acid, pitavastatin calcium, lamivudine, 
adefovir, and entecavir. Under the suspicion of drug-induced 
rhabdomyolysis, pitavastatin calcium intake was discontinued 
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first; however, serum CPK continued to rise, and on February 26 
and 27, the level reached 18,818 IU/l and 21,633 IU/l, respectively. 
Next, administration of lamivudine was discontinued, leading to 
a continuous drop in the level of serum CPK, that reached 172 
IU/l, 116 IU/l on March 7 and 14, respectively (Fig.1). From the 
above clinical course, lamivudine was identified as the cause of 
rhabdomyolysis.
Rhabdomyolysis is encountered in cases of trauma, 
myocardial infarction, metabolic or genetic disorders, infections, 
prolonged surgery, and drug administration. 
Lamivudine has few adverse reactions and is very safe, 
especially that its adverse effects, other than induction of the 
YMDD-variant virus and post treatment ﬂares, are believed to be 
rare [1]. In the literature, however, drug-induced rhabdomyolysis 
is associated with several factors, including prophylactic 
administration of lamivudine and treatment of HBV infection 
[2, 3]. Two cases of rhabdomyolysis with renal failure attributed 
to lamivudine administration have been reported: one in a liver 
transplant recipient [2], and another one of acute exacerbation 
Available from: http://www.jgld.ro/wp/archive/y2015/n4/a22
Fig. 1. Creatine phosphokinase (CPK) and creatinine (CRE) levels in 
our patient from February 10, 2014 to March 19, 2014.
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of chronic hepatitis B [3]. In the former, even the rechallenge test 
and dialysis were carried out; in the latter, the patient died without 
undergoing dialysis. In the present case, because of intravenous 
drip transfusion therapy, renal function tests such as serum 
creatinine and azotemia were maintained within normal limits, 
and renal failure and dialysis were obviated.
The rechallenge test was not carried out in this patient from 
the viewpoint of medical ethics.
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“Learning curve“ for the POEM procedure
To the Editor,
Many recent published manuscripts have addressed the 
clinical efficiency of peroral endoscopic myotomy (POEM) 
procedure for achalasia [1-3] and some of them have focused 
in particular on the learning curve of this technique [3-6]. 
The learning process was analyzed through miscellaneous 
parameters (the procedure time, the accidental mucosotomies, 
the severe complication rate, the significant improvement of 
dysphagia), without standardization as it reflects a recently 
developed endoscopic procedure. Some studies tried to 
define a case number threshold for becoming an expert of 
the POEM procedure. In smaller case series with the main 
outcome defined as the procedure time, conflicting results 
were reported. Kurian et al. [4] reported that the mastery of the 
operative technique in POEM was achieved after 20 procedures 
and evidenced by a decrease in the length of procedure, but 
Teitelbaum et al. [5] concluded that the overall procedure time 
did not decrease with experience and may not be an important 
marker of procedural skill for POEM. Patel et al. [6] analyzed 
93 procedures with multiple parameters that might influence 
the learning curve and concluded that efficiency was attained 
after 40 POEMs and mastery after 60 POEMs. In this study, 
the adjusted regression analysis showed that the procedure 
time was significantly influenced by the case numbers of the 
operator (p<.0001), but the improvements in clinical outcomes 
were not significantly affected by operator experience. In the 
multicenter retrospective analysis published by Werner et al. 
[3], the authors analyzed the possible impact of the learning 
curve on POEM failures and compared the first 10 cases 
included on each center (30) with post-10 procedures (50) 
and found no significant impact of the learning curve on the 
cumulative rates of patients with failure (p=0.513). 
Our experience consists of 42 POEM procedures performed 
on 19 men and 23 women with a median age of 44 years 
(range 24-70 years) and a median for the Eckardt score of 7 
(range 4-12).  Mean symptom period was 30 months (range 
2-100 months). Five (11.9%) patients had previous endoscopic 
treatment (one or two sessions of esophageal balloon 
dilatation), while one patient had undergone laparoscopic 
Heller myotomy 2 years previously. Mean lower esophageal 
sphincter resting pressure before treatment was 38 mmHg 
(range 20-70, standard deviation 16.5 mmHg). The POEM 
technique was performed by an expert endoscopist. All 
patients experienced symptom improvement immediately after 
the procedure. The mean myotomy length was 15 cm (range 
13-18 cm). The mean number of endoscopic clips used to 
safely close the mucosal breach was 10 (range 5-31, standard 
deviation 5.8). The mean procedural time for POEM was 82 
minutes (range 35-180 minutes) (with a mean of 81.85 minutes 
for the first 20 procedures and 82.95 minutes for the next 22 
procedures). Seven (16.6%) incidents were recorded during 
POEM: 3 esophageal and gastric mucosal micro-perforations 
safely closed with clips, 1 subcutaneous emphysema and 3 
instances of pneumoperitoneum, resolved with decompression 
using the Veress needle. No referral to surgery was needed. 
Post procedurally, 5 (11.1%) cases of subcutaneous emphysema 
associated with mild pneumoperitoneum and 15 (35.7%) cases 
of isolated mild pneumoperitoneum were detected and all 
were resolved spontaneously. No infectious or hemorrhagic 
complications were noted. Median hospital stay was 5 days 
(range 4-15 days). One month follow up depicted a significant 
decrease for median Eckardt scores from 7 to 0 (Wilcoxon test, 
p<0.005). Only one patient out of 30 still experienced dysphagia 
at one-year follow up. 
The literature data and our own experience argued that the 
learning process of POEM did not influence the main outcome, 
i.e. the dysphagia improvement. The other parameters 
reported such as the procedure time and the complication 
rate can be biased by the operators’ previous experience 
with other difficult endoscopic procedures (mucosectomies 
or submucosal dissection) and complications management. 
Another aspect that might influence this learning process is 
the case management selection for POEM based on previous 
endoscopic experience of operators with achalasia treatment 
and on patients’ past achalasia history.  
According to our results, the learning process for POEM 
does not influence improvement in dysphagia and mastery 
might be achieved when difficult achalasia cases are resolved 
by this technique.
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Balloon dilatation with or without 
intralesional and oral corticosteroids for 
anastomotic Crohn’s disease strictures
To the Editor,
Stricture formation is a common and challenging 
complication in patients with Crohn’s disease (CD) leading 
to repeated surgery and endoscopic balloon dilatations 
(EBDs)[1, 2]. Although EBD is an effective bowel-conserving 
treatment,  fifty per cent of patients will require repeated 
dilatations [3]. The long-term outcome of EBD may be 
improved by intralesional injection of corticosteroids. 
However, data regarding the efficacy of intralesional steroids 
remain conflicting [4]. Therefore, we examined whether adding 
intralesional triamcinolone injections and oral budesonide for 
24 weeks to EBD reduces the recurrence of strictures and the 
need for repeat dilatation and/or surgery.
We performed a multicentre, double-blinded trial (Dutch 
Trial Registration no. 1378), including adult CD patients with 
a clinically significant symptomatic stricture of the ileocecal 
anastomosis who underwent routine EBD. Patients with 
infectious colitis, extensive inflammation or fistulas at the site 
of stricture, and stricture length > 5 cm were excluded. EBD 
was repeated until a significant dilatation of the stricture was 
accomplished. Patients were randomly assigned to either four-
quadrant injections of 0.5-1 mL triamcinolone (Kenacort 40 
mg/mL) followed by oral budesonide for 24 weeks (tapered 
from 9 to 3 mg) or saline injections followed by placebo 
capsules. Follow-up data, including obstructive symptoms 
(VAS scores), clinical disease activity, and adverse events 
were collected at week 2, 6, 12, 24 and 52. The primary end 
point was the recurrence of a clinically significant stricture 
necessitating re-dilatation or surgery. Secondary end points 
were rates of clinical improvement and remission according 
to VAS scores. Clinical remission and clinical response were 
defined as a total VAS score ≤ 5 and a ≥50% decrease in total 
VAS score, respectively.
Nine patients (mean age 52±10 years; 33% male) were 
randomized, 5 to corticosteroid treatment and 4 to placebo. 
Groups were not significantly different with regard to 
baseline and stricture characteristics. In the intention-to-
treat analysis, 1 out of 5 patients in the corticosteroid group 
required surgery and 1 out of 4 patients in the placebo group 
required redilatation (Cox regression p = 0.94, HR 0.89; 95% 
Fig. 1. Proportion of patients in clinical remission on week 2, 6, 12, 
24 and 52 allocated to placebo and corticosteroid treatment. Clinical 
remission is defined as a total VAS score ≤ 5 of obstructive symptoms 
(intermittent abdominal pain, abdominal distension, nausea, vomiting 
and anorexia).
Fig. 2. Proportion of patients with clinical response on week 2, 6, 
12, 24 and 52 allocated to placebo and corticosteroid treatment. 
Clinical response is defined as a ≥50% decrease in total VAS score 
of obstructive symptoms (intermittent abdominal pain, abdominal 
distension, nausea, vomiting and anorexia).
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CI 0.06-14.4). Except for week 6, no difference in the rate of 
clinical remission was detected between the corticosteroid 
and placebo group at week 2 (20 vs. 0%, p=0.556), week 12 
(p=0.595), week 24 (20 vs. 50%, p=0.405), and week 52 (20 
vs. 0%, p=0.556) (Fig. 1). Additionally,  apart from week 24, 
response rates were not different between the corticosteroid 
and placebo group (Fig. 2). No major adverse events occurred 
during follow-up. 
In conclusion, intralesional and oral topical corticosteroids 
did not reduce the need for redilatation after EBD of CD 
ileocolonic anastomotic strictures. Several reasons may explain 
this negative finding. First, intralesional steroids might lead to 
postdilational stricture ischemia and inflammation [5]. Second, 
inflammatory strictures, which may be more susceptible to 
treatment with corticosteroids, were not included in our study. 
Cautious interpretation of this negative finding is warranted, 
as a type II error is possible. However, considering our 
results and previous evidence [4, 6] we feel that intralesional 
corticosteroids as an adjuvant should not be implemented into 
clinical practice.
Mike van der Have1, Casper Noomen2, Bas Oldenburg1, Daisy 
Walter1, Martin H.M.G. Houben3, Martin N. Wasser4, Peter D. 
Siersema1, Daan Hommes5,6, Herma H. Fidder1
1) Department of Gastroenterology and Hepatology, University 
Medical Center Utrecht, Utrecht; 2) Department of Gastroenterology 
and Hepatology, Alkmaar Medical Center, Alkmaar; Department 
of Gastroenterology, Haga Hospital, The Hague; 3) Department of 
Radiology, Leiden University Medical Center, Leiden; 4) Department 
of Gastroenterology and Hepatology, Leiden University Medical 
Center, Leiden, The Netherlands; 5) Center for Inflammatory Bowel 
Diseases, UCLA Health System, Los Angeles, USA
Correspondence: Mike van der Have, M.vanderhave@umcutrecht.nl
Conflicts of interest: The authors declare no conflict of interests.
Table I. Baseline and stricture characteristics in our patients
Variable All patients (n = 22) Corticosteroid (n = 5) Placebo (n = 4)
Age, mean (±SD) 46.1 (12.0) 49.1 (11.1) 56.5 (8.4)
Male, n (%) 10 (45.5) 1 (20.0) 1 (25.0)
Smoker, n (%) 7 (31.8) 1 (20.0) 1 (25.0)
Disease duration, median (IQR) 18.4 (10.9-33.8) 14.9 (9.7-38.2) 29.2 (8.4-41.0)
Montreal classification, n (%)
L1 ileal 11 (50.0) 4 (80.0) 0 (0.0)
L3 ileocolonic 11 (50.0) 1 (20.0) 4 (100.0)
+ upper GI 1 (4.5) 0 (0.0) 0 (0.0)
B3 penetrating 3 (13.6) 1 (20.0) 0 (0.0)
+ perianal disese 5 (22.7) 1 (20.0) 0 (0.0)
Time since ileocecal resection, 
median (IQR), years
10.0 (4.9-25.8) 10.1 (2.1-38.1) 18.1 (0-37.9)
Current medication use, n (%)
5-ASA 2 (9.1) 1 (20.0) 0 (0.0)
Immunomodulators 8 (36.4) 1 (20.0) 1 (25.0)
Anti-TNF agents 7 (31.8) 3 (60.0) 1 (25.0)
Disease activity, mean (±SD)a 6.7 (3.7) 7.0 (2.8) 6.3 (5.0)
C-reactive protein level, mean 
(±SD), mmol/L
3.8 (2.0) 4.2 (2.7) 3.0 (0.5)
Obstructive symptoms, mean (±SD)
Abdominal pain 4.4 (2.3) 4.0 (1.8) 2.4 (2.0)
Abdominal distension 5.2 (2.6) 5.4 (2.5) 5.6 (3.7)
Nausea 3.6 (2.7) 1.3 (2.5) 6.6 (1.9)
Vomiting 1.6 (2.0) 0.2 (0.4) 2.2 (2.1)
Anorexia 3.5 (2.5) 0.8 (0.9) 3.0 (1.5)
Stricture length by MR enterography, 
median (IQR), cm
3.5 (1.3-5.0)b 2.6 (0.9-4.7) 3.3 (1.5-6.9)
Stricture length by ultrasound, 
median (IQR), cm
3.2 (2.0-4.2)c 2.9 (2.1-5.3) 3.5 (3.5-7)
Maximal balloon size, median (IQR), 
mm
- 18 (16-18) 18 (14-18)
a = according to the Harvey Bradshaw Index; b = MR enterography available for 19 patients; c = abdominal 
ultrasound available for 18 patients
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Validation of the Bristol Stool Form Scale 
into Romanian
To the Editor,
Data on stool form and consistency is very important 
when approaching patients with digestive diseases [1] or other 
conditions associated with changes of the bowel transit, such as 
endocrine diseases [2]. One of the most frequent and common 
functional gastrointestinal diseases is irritable bowel syndrome 
(IBS) [3], where the altered bowel transit represents one of the 
diagnostic criteria [1], thus making the assessment of bowel 
transit mandatory.
The most widely used and known tool for the analysis 
of bowel habit and stool type is the Bristol Stool Form Scale 
(BSFS) [4-6], with an efficacy that has been already proven in 
studies and in clinical practice [4, 7, 8].  To our knowledge, 
no translation or validation of the BSFS has been performed 
into Romanian, therefore we decided to translate and validate 
the scale into Romanian, in order to offer to healthcare and/
or scientific professionals a simple and efficient tool to analyze 
the stools of their patients. 
The study was approved by the local Ethics Committee. 
Permission for the translation and validation of the BSFS was 
authorised by the Norgine group of companies, which holds 
the copyright, conceded by the authors.
Translation into Romanian was performed similarly to 
previous validation studies: by two authorized translators, 
then two gastroenterologists adapted the translation, which 
was further translated back into English by two bilingual 
specialists, a physician and a native English and Romanian 
speaker. The final form was applied to a pilot group consisting 
of 12 medical professionals and 6 patients, in order to detect 
possible problems (see Supplementary material).
We investigated 120 healthcare professionals (30 physicians, 
specialists in internal medicine and/or gastroenterology, 
30 medical residents, 30 nurses and 30 third-year medical 
students) and 60 patients, of whom 30 with IBS (14: IBS-C, 
10: IBS-D, 6: IBS-M) and 30 with various other conditions 
recruited from the Internal Medicine and Gastroenterology 
Departments. The group included 54 males and 126 females 
with a median age 38.36 years; 13.34% (8 patients) with higher 
education, 40% (24 patients) with secondary education, and 
46.66% (28 patients) with elementary education. All subjects 
were invited to match one randomly selected spoken text (in 
Romanian) defining one of the seven types of stools with one of 
the seven drawings from the original scale. This was performed 
twice for each subject, resulting in two pairs of question-
answers. For re-test reliability a randomly selection of 10% 
of subjects were invited to repeat the procedure after 14 days. 
The overall value for Cronbach‘s alpha was 0.892 for the 
first pair of questions and answers, respectively 0.953 for the 
second pair (ranges 0.844 - 1), indicating adequate test-re-test 
reliability and internal consistency for each subgroup [9].
The intraclass correlation coefficient (ICC) that ensures the 
reproducibility of a scale or questionnaire by measuring the 
consistency or homogeneity of measurements was 0.805 for 
the first pair, and 0.911 for the second pair question-answer, 
respectively. Excellent reliability [10, 11] with value ≥ 0.90 indicates 
small bias [12], supporting the reliability of the translated scale.  
This study confirms that the Romanian version of the BSFS 
proposed by us is reliable and can be used to evaluate stool 
form and consistence.
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Tip 1
Reproduced with kind permission of Dr KW Heaton,
formerly Reader in Medicine at the University of Bristol. 
©2000, Norgine group of companies.
Bucăți mari separate,
asemănătoare cu nucile
(greu de eliminat)
Cu formă de cârnat,
dar constituit din bucăți 
(tare)
Asemănător unui cârnat,
dar cu crăpături
la  (pe) suprafaţă
Asemănător unui cârnat
sau unui şarpe,
neted şi moale
Fragmente moi cu
margini bine definite 
(uşor de eliminat)
Bucăţi pufoase
cu margini neregulate,
scaun moale
Apos, fără bucăţi solide.
COMPLET LICHID
Scala Bristol a formei scaunului
